Compound Summary
Compound Information
etodolac
Compound Name: | etodolac |
Compound CID: | 3308 |
Synonyms: | etodolac 41340-25-4 Etodolic acid Lodine Ultradol More... |
Iupac Name: | 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid |
InChI: | InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20) |
InChIKey: | NNYBQONXHNTVIJ-UHFFFAOYSA-N |
Canonical Smiles: | CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O |
Isomeric Smiles: | CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O |
Molecular Weight: | 287.35 |
Molecular Formula: | C17H21NO3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
etodolac
Molecular Weight: | 287.35 |
Molecular Formula: | C17H21NO3 |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 3 |
Rotatable Bond Count: | 4 |
Heavy Atom Count: | 21 |
Complexity: | 400 |
Synonyms
etodolac
| etodolac | etodolac |
|---|---|
etodolac |
41340-25-4 |
Etodolic acid |
Lodine |
Ultradol |
Lodine XL |
AY-24236 |
Etodolaco |
Etodolacum |
AY 24236 |
AY-24,236 |
Edolan |
2-(1,8-diethyl-1,3,4,9-tetrahydropyrano3,4-bindol-1-yl)acetic acid |
1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid |
1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid |
1,8-Diethyl-1,3,4,9-tetrahydropyrano3,4-bindole-1-acetic acid |
2-(1,8-diethyl-4,9-dihydro-3H-pyrano3,4-bindol-1-yl)acetic acid |
Pyrano3,4-bindole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- |
CHEMBL622 |
(1,8-Diethyl-1,3,4,9-tetrahydropyrano3,4-bindol-1-yl)acetic acid |
MLS000028474 |
CHEBI:4909 |
RAK-591 |
2-{1,8-diethyl-1H,3H,4H,9H-pyrano3,4-bindol-1-yl}acetic acid |
(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano3,4-bindol-1-yl)-acetic acid |
Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- |
NSC282126 |
NSC-282126 |
Ramodar |
SMR000058443 |
DSSTox_CID_615 |
(+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid |
(RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano3,4-bindol-1-yl)acetic acid |
Etodolacum INN-Latin |
DSSTox_RID_75691 |
DSSTox_GSID_20615 |
Etodolaco INN-Spanish |
Hypen |
1,8-diethyl-1,3,4,9-tetrahydro-pyrano3,4-bindole-1-acetic acid |
1,8-diethyl-1,3,4,9-tetrahydropyrano3,4-bindol-1-ylacetic acid |
CCRIS 3923 |
SR-01000000100 |
NSC 282126 |
Osteluc |
Tedolan |
Zedolac |
etodolac o |
rac-Etodolac |
Etodlic Acid |
MFCD00133313 |
Lodine SR |
KS-1056 |
Etodolac USAN:USP:INN:BAN |
Etodolac- Bio-X |
NCGC00016849-01 |
Etodolac,(S) |
Prestwick_209 |
CAS-41340-25-4 |
Lodine (TN) |
Spectrum_001244 |
Opera_ID_1774 |
Prestwick0_000231 |
Prestwick1_000231 |
Prestwick2_000231 |
Prestwick3_000231 |
Spectrum2_001387 |
Spectrum3_001429 |
Spectrum4_000410 |
Spectrum5_001347 |
SCHEMBL3903 |
Lopac0_000479 |
BSPBio_000301 |
BSPBio_003138 |
KBioGR_000680 |
KBioSS_001724 |
MLS001077315 |
MLS006011566 |
DivK1c_000147 |
SPECTRUM1501005 |
Etodolac (JP17/USP/INN) |
SPBio_001374 |
SPBio_002222 |
BPBio1_000333 |
GTPL7185 |
DTXSID9020615 |
HMS500H09 |
KBio1_000147 |
KBio2_001724 |
KBio2_004292 |
KBio2_006860 |
KBio3_002358 |
NINDS_000147 |
HMS1568P03 |
HMS1921B09 |
HMS2092O20 |
HMS2095P03 |
HMS2231D04 |
HMS3259P10 |
HMS3261O20 |
HMS3374G09 |
HMS3712P03 |
Pharmakon1600-01501005 |
BCP28411 |
NIH-9918 |
Tox21_110644 |
Tox21_202218 |
Tox21_500479 |
BDBM50016799 |
CCG-39005 |
CE0096 |
NSC757821 |
Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl- |
AKOS015838610 |
Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)- |
Tox21_110644_1 |
AC-4231 |
CS-0832 |
DB00749 |
LP00479 |
NC00718 |
NSC-757821 |
SDCCGSBI-0050463.P004 |
IDI1_000147 |
NCGC00015399-03 |
NCGC00015399-04 |
NCGC00015399-05 |
NCGC00015399-06 |
NCGC00015399-07 |
NCGC00015399-08 |
NCGC00015399-09 |
NCGC00015399-11 |
NCGC00015399-12 |
NCGC00015399-13 |
NCGC00015399-15 |
NCGC00015399-16 |
NCGC00015399-26 |
NCGC00089769-02 |
NCGC00089769-03 |
NCGC00089769-04 |
NCGC00089769-05 |
NCGC00089769-06 |
NCGC00089769-07 |
NCGC00259767-01 |
NCGC00261164-01 |
BR164431 |
HY-76251 |
SBI-0050463.P003 |
AB0012214 |
AY-24-236 |
AB00052194 |
E0858 |
EU-0100479 |
FT-0607046 |
FT-0668424 |
FT-0668425 |
C06991 |
D00315 |
E 0516 |
Pyrano3, 1,8-diethyl-1,3,4,9-tetrahydro- |
AB00052194_17 |
340E254 |
Q-201099 |
Q2465218 |
SR-01000000100-2 |
SR-01000000100-4 |
SR-01000000100-7 |
BRD-A74667430-001-05-3 |
BRD-A74667430-001-15-2 |
1,3,4,9-tetrahydropyrano3,4-bindole-1-acetic acid |
Etodolac, European Pharmacopoeia (EP) Reference Standard |
F2173-0681 |
Z1820178466 |
Etodolac, United States Pharmacopeia (USP) Reference Standard |
1,8-Diethyl-1,3,4,9-tetrahydropyranol3,4-bindole-1-acetic acid |
(+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid |
2-(1,8-diethyl-4,9-dihydro-3H-pyrano3,4-bindol-1-yl)acetic acid. |
Pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl- |
AY 24,236; AY 24236;AY-24,236; AY-24236; AY24,236; AY24236 |
Etodolac for peak identification, European Pharmacopoeia (EP) Reference Standard |
Experimental Data
etodolac
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -9 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
etodolac
Statistics Data
etodolac
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -9 | 1 | 1 |
Statistics Data Visualization
etodolac
